Results 71 to 80 of about 72,300 (203)
Achromobacter : mechanisms of acquired resistance to fluoroquinolones
, 2022 Achromobacter est un pathogène opportuniste émergent, rencontré principalement chez les patients atteints de mucoviscidose. Ce sont des bacilles à Gram négatif non fermentaires présentant des résistances naturelles à de nombreux antibiotiques ainsi que ...
Magallon, Arnaud
core
Fluoroquinolones in ambulatory surgical practice: whom, when, how?
Амбулаторная хирургия, 2016 The articLe discusses the indications and conditions for the use of fLuoroquinoLones (ciprofloxacin, LevofLoxacin, moxifLoxacin) in surgicaL infections of the skin and soft tissues in ambuLatory patients.
A. V. Golub +2 more
doaj
New Microbes and New Infections, 2015 Helicobacter pylori causes peptic ulceration and gastric adenocarcinoma. The aims were to study the influence of dupA1 positivity upon interleukin-8 (IL-8) secretion from gastric mucosa and determine the prevalence of mutations responsible for ...
N.R. Hussein +5 more
doaj +1 more source
Antimicrobial Drug Prescribing for Pneumonia in Ambulatory Care
Emerging Infectious Diseases, 2005 To determine patterns and predictors of antimicrobial drug use for outpatients with community-acquired pneumonia, we examined office visit and pharmacy claims data of 4 large third-party payer organizations from 2000 to 2002.
Conan MacDougall +3 more
doaj +1 more source
Fluoroquinolones for Treating Tuberculosis
, 2017 Tuberculosis (TB) remains a significant global health and socioeconomic challenge. The duration of current anti-TB therapies, the adverse effects of certain anti-TB drugs and the growing problem of drug-resistant TB on an international scale mean that it
McHugh, TD, Lipman, MCI, Kumar, K
core +1 more source
Fluoroquinolone use restrictions in patients with uncomplicated infections and safety issues [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2017 n May 2016, US FDA advised to restrict fluoroquinolones use in patients with acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections.
Ushkalova E.A., Zyryanov S.K.
doaj
Antibiotics, 2019 The Food and Drug Administration (FDA) safety review revealed that the use of fluoroquinolones (FQs) is linked with disabling and potentially permanent serious adverse effects.
Benitta Mathews +5 more
doaj +1 more source
N1-Benzofused Modification of Fluoroquinolones Reduces Activity Against Gram- Negative Bacteria [PDF]
, 2019 The fluoroquinolone class of antibiotics have a well-established structure-activity relationship (SAR) and a long history in the clinic, but the effect of electron-rich benzofused substituents at the N1 position remains poorly explored.
Mark, Laws +11 more
core +2 more sources
, 2009 The genes encoding the subunits of DNA topoisomerase IV (parC and parE) and DNA gyrase (gyrA and gyrB) of Streptococcus pneumoniae were cloned and overproduced in Escherichia coli by using the T7promoter-T7 RNA polymerase system.
Balas, Delia +3 more
core +1 more source
Modelled PNECs for macrolides and fluoroquinolones [55].
, 2019 Modelled PNECs for macrolides and fluoroquinolones [55].
Virginie D. J. Keller (7344653) +2 more
core +1 more source